U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Development Resources
  5. Doripenem – Injection products
  1. Development Resources

Doripenem – Injection products

Recognized Interpretive Criteria

Exceptions to the recognized standard of CLSI M100

 

Minimum Inhibitory
Concentrations

(mcg/mL)

Disk Diffusion
(zone diameter in mm)

Pathogen

S

I

R

S

I

R

Enterobacterales

M100 standard is recognized

Pseudomonas aeruginosa

M100 standard is recognized

Acinetobacter spp.

M100 standard is recognized

Streptococcus spp Viridans
Group

M100 standard is recognized

 ≥ 24

-

-

Anaerobes

≤ 1

-

-

-

-

-

S = Susceptible; I = Intermediate; R = Resistant

For the bacteria listed below, susceptibility test interpretive criteria are not recognized at this time:

Haemophilus influenzae and parainfluenzae

Streptococcus pneumonia

Streptococcus spp. β-Hemolytic Group

Back to Top